Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors

Journal of Clinical Virology

Volumn 13, Issue 1-2, 1999, Pages 71-80

  Walter, Hauke ^a   Schmidt, Barbara ^a   Korn, Klaus ^a   Vandamme, Anne Mieke ^b   Harrer, Thomas ^a   Überla, Klaus ^a,c  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Antiretroviral therapy; HIV; Resistance

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE;

ASSAY; BACTERIUM TRANSFORMATION; CODON; CONFERENCE PAPER; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; GENE DELETION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VIRUS GENE; VIRUS RECOMBINANT;

ANTI-HIV AGENTS; CELL LINE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS;

EID: 0033033193     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(99)00010-4     Document Type: Conference Paper

References (17)

1. Balzarini J., Karlsson A., Perez-Perez M.J., Camarasa M.J., Tarpley W.G., De Clercq E. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J. Virol. 67:1993;5353-5359.
2. Boucher C.A., Keulen W., van Bommel T., Nijhuis M., de Jong D.J.M., Schipper P., Back N.K. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob. Agents Chemother. 40:1996;2404-2409.
3. Condra J.H., Schleif W.A., Blahy O.M., Gabryelski L.J., Graham D.J., Quintero J.C., Rhodes A., Robbins H.L., Roth E., Shivaprakash M., Titus D., Yang T., Teppler H., Squires K.E., Deutssch P.J., Emini E.A. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 374:1995;569-571.
4. Hertogs K., de Bethune M.P., Miller V., Ivens T., Schel P., Van Cauwenberge A., Van Den Eynde C.G.V., Azijn H., Van Houtte M., Peeters F., Staszewski S., Conant M., Bloor S., Kemp S., Larder B., Pauwels R. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:1998;269-276.
5. Johnson V., Byington R.E. Quantitative assays for virus infectivity. Aldovini A., Walker B.D. Techniques in HIV research. 1990;71-76 Stockton Press, New York.
6. Kellam P., Larder B.A. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38:1994;23-30.
7. Kemp S.D., Shi C., Bloor S., Harrigan P.R., Mellors J.W., Larder B.A. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′3′-dideoxy-3′-thiacytidin. J. Virol. 72:1998;5093-5098.
8. Larder B.A., Kellam P., Kemp S.D. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature. 365:1993;451-453.
9. Mammano F., Petit C., Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J. Virol. 72:1998;7632-7637.
10. Maschera B., Furfine E., Blair E.D. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J. Virol. 69:1995;5431-5436.
11. Means R.E., Greenough T., Desrosiers R.C. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J. Virol. 71:1997;7895-7902.
12. Perrin L., Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science. 280:1998;1871-1873.
13. Schinazi R.F., Larder B.A., Mellors J. Mutations in retroviral genes associated with drug resistance. Int. Antivir. News. 5:1997;129-140.
14. Schmit J.C., Ruiz L., Clotet B., Raventos A., Tor J., Leonard J., Desmyter J., De Clercq E., Vandamme A.M. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS. 10:1996;995-999.
15. Tisdale M., Kemp S.D., Parry N.R., Larder B.A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA. 90:1993;5653-5656.
16. Zennou V., Mammano F., Paulous S., Mathez D., Clavel F. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72:1998;3300-3306.
17. Zhang Y.M., Imamichi H., Imamichi T., Lane H.C., Falloon J., Vasudevachari M.B., Salzman N.P. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:1997;6662-6670.